Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	1.93T -4.4%
Revenue (ttm)	1.38T +5.0%
Net Income	136.01B +157.9%
EPS	2,007.05 +157.6%
Shares Out	67.71M
PE Ratio	14.17
Forward PE	n/a
Dividend	300.00 (0.95%)
Ex-Dividend Date	Mar 30, 2026

Volume	144,228
Open	29,200
Previous Close	31,650
Day's Range	28,100 - 30,200
52-Week Range	28,200 - 55,500
Beta	0.50
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult’s bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition, it offers automated drug management systems. The company sells its products through online and offline pharmacies. The company was formerly known as ...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Employees: 476
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2025, Hanmi Science's revenue was 1.36 trillion, an increase of 5.73% compared to the previous year's 1.28 trillion. Earnings were 118.37 billion, an increase of 99.20%.